98%
921
2 minutes
20
Therapeutic drug monitoring (TDM) of imatinib (IM) in cancer therapy offers the potential to improve treatment efficacy while minimizing toxicity. There was a significant correlation between unbound concentration and clinical response and toxicity, compared with total plasma concentrations, and the quantification of unbound IM and its metabolite, N-desmethyl imatinib (NDI) are of interest for TDM. However, traditional unbound drug separation methods have shortcomings, especially are susceptible to non-specific binding (NSB) of drugs to the polymer-constructed components of filter membranes, which are difficult to avoid at present. Hence it is necessary to developed a reliable separation method for the analysis of the unbound fraction of IM and NDI in TDM. We developed and validated an hollow fiber solid phase microextraction (HF-SPME) method coupled with high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) that to measure unbound IM and NDI concentration in human plasma. It used the NSB phenomenon and solve the NSB problem. The preparation procedure only involves a common vortex and ultrasonication without dilution of samples and modification of membrane. A total of 50 chronic myeloid leukemia (CML) patients were enrolled in our study. The relationship between the unbound and total concentrations for IM and NDI, as well as the concentration ratios of NDI to IM in 50 clinical plasma samples were investigated. The extraction recovery is high to 95.5-106 % with validation parameters for the methodological results were all excellent. There were both a poor linear relationship between the unbound and total concentrations for IM (r=0.504) and NDI (r=0.201) in 50 clinical plasma samples. The unbound concentration ratios of NDI to IM varied widely in CML patients. The determination of unbound IM and NDI concentration is meaningful and necessary. The developed HF-SPME method is simple, accurate and precise that could be used to measure unbound IM and NDI concentration in clinical TDM.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jpba.2024.116405 | DOI Listing |
J Pharm Biomed Anal
November 2024
The School of Medicine, Nankai University, Tianjin 300071, China; Department of Orthopaedics, Hebei Medical University Third Hospital, Shijiazhuang, Hebei Province 050000, China. Electronic address:
Therapeutic drug monitoring (TDM) of imatinib (IM) in cancer therapy offers the potential to improve treatment efficacy while minimizing toxicity. There was a significant correlation between unbound concentration and clinical response and toxicity, compared with total plasma concentrations, and the quantification of unbound IM and its metabolite, N-desmethyl imatinib (NDI) are of interest for TDM. However, traditional unbound drug separation methods have shortcomings, especially are susceptible to non-specific binding (NSB) of drugs to the polymer-constructed components of filter membranes, which are difficult to avoid at present.
View Article and Find Full Text PDFComput Math Methods Med
July 2012
Department of Mathematics, Natural and Computer Sciences, Hochschule Mittweida, University of Applied Sciences, Technikumplatz 17, 09648 Mittweida, Germany.
Diabetes insipidus (DI) is a rare endocrine, inheritable disorder with low incidences in an estimated one per 25,000-30,000 live births. This disease is characterized by polyuria and compensatory polydypsia. The diverse underlying causes of DI can be central defects, in which no functional arginine vasopressin (AVP) is released from the pituitary or can be a result of defects in the kidney (nephrogenic DI, NDI).
View Article and Find Full Text PDFTher Drug Monit
October 2011
Central Laboratory, Department of Clinical Chemistry, University Medical Center, George-August-University, Goettingen, Germany.
Objectives: Trough total imatinib (t-IM) concentrations have been reported to be associated with therapeutic and toxic responses in patients with chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST). Little is known about the relationships between effects and concentrations of either unbound imatinib (f-IM) or imatinib's major metabolite, N-desmethyl imatinib (NDI). In part, this is because of the lack of a single, validated, well-described clinically useful assay for these measurements.
View Article and Find Full Text PDFPoly-l-lysine (PL) binds to about 50% of chromatin DNA, rendering it resistant to degradation by DNAase I. Separation of the unbound DNA as acid-soluble nucleotides allows the fractionation of chromatin DNA into two zones. After in vivo administration of N,N-di[14C]methylnitrosamine, the amount of alkylation in DNA was found to be lower in the polylysine-binding regions.
View Article and Find Full Text PDF